Kintor Pharma Reports Stable Share Capital and Public Float in August 2026

Bulletin Express

3 hours ago

Kintor Pharmaceutical Limited (Kintor Pharma) filed its monthly return for the period ended 31 August 2026, showing no changes in either authorised or issued share capital.

Authorised Capital • Remained at 700.00 million ordinary shares with a par value of USD 0.0001, equivalent to USD 0.07 million in authorised share capital.

Issued Shares • Outstanding shares stayed flat at 498.66 million. • The company held no treasury shares.

Public Float Compliance • Kintor Pharma confirmed adherence to the Hong Kong Stock Exchange’s minimum public-float requirement of 25 % of issued shares.

Corporate Actions • The filing recorded no share options, warrants, convertible instruments, or other equity-linked agreements during the month.

The unchanged share structure underscores a period of capital stability for Kintor Pharma through the end of August 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/news/1128892813"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1128892813\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1128892813?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-01 17:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128892813","market":"hk","top_or_hot":-1,"title":"Kintor Pharma Reports Stable Share Capital and Public Float in August 2026","media":"Bulletin Express","content":"<p>Kintor Pharmaceutical Limited (Kintor Pharma) filed its monthly return for the period ended 31 August 2026, showing no changes in either authorised or issued share capital.</p>\n<p>Authorised Capital  \n• Remained at 700.00 million ordinary shares with a par value of USD 0.0001, equivalent to USD 0.07 million in authorised share capital.</p>\n<p>Issued Shares  \n• Outstanding shares stayed flat at 498.66 million.  \n• The company held no treasury shares.</p>\n<p>Public Float Compliance  \n• Kintor Pharma confirmed adherence to the Hong Kong Stock Exchange’s minimum public-float requirement of 25 % of issued shares.</p>\n<p>Corporate Actions  \n• The filing recorded no share options, warrants, convertible instruments, or other equity-linked agreements during the month.</p>\n<p>The unchanged share structure underscores a period of capital stability for Kintor Pharma through the end of August 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kintor Pharma Reports Stable Share Capital and Public Float in August 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKintor Pharma Reports Stable Share Capital and Public Float in August 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-09-01 17:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Kintor Pharmaceutical Limited (Kintor Pharma) filed its monthly return for the period ended 31 August 2026, showing no changes in either authorised or issued share capital.</p>\n<p>Authorised Capital  \n• Remained at 700.00 million ordinary shares with a par value of USD 0.0001, equivalent to USD 0.07 million in authorised share capital.</p>\n<p>Issued Shares  \n• Outstanding shares stayed flat at 498.66 million.  \n• The company held no treasury shares.</p>\n<p>Public Float Compliance  \n• Kintor Pharma confirmed adherence to the Hong Kong Stock Exchange’s minimum public-float requirement of 25 % of issued shares.</p>\n<p>Corporate Actions  \n• The filing recorded no share options, warrants, convertible instruments, or other equity-linked agreements during the month.</p>\n<p>The unchanged share structure underscores a period of capital stability for Kintor Pharma through the end of August 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09939","symbol_name":"开拓药业-B","start_time":0,"source_url":"","article_id":"1128892813","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128892813","pubTimestamp":1788255320,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Kintor Pharmaceutical Limited (Kintor Pharma) filed its monthly return for the period ended 31 August 2026, showing no changes in either authorised or issued share capital. Authorised Capital   •...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09939":"开拓药业-B"},"translate_title":"开拓医药报告 2026 年 8 月股本和公众持股量稳定","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09939":1},"content_text":"Kintor Pharmaceutical Limited (Kintor Pharma) filed its monthly return for the period ended 31 August 2026, showing no changes in either authorised or issued share capital.\nAuthorised Capital  \n• Remained at 700.00 million ordinary shares with a par value of USD 0.0001, equivalent to USD 0.07 million in authorised share capital.\nIssued Shares  \n• Outstanding shares stayed flat at 498.66 million.  \n• The company held no treasury shares.\nPublic Float Compliance  \n• Kintor Pharma confirmed adherence to the Hong Kong Stock Exchange’s minimum public-float requirement of 25 % of issued shares.\nCorporate Actions  \n• The filing recorded no share options, warrants, convertible instruments, or other equity-linked agreements during the month.\nThe unchanged share structure underscores a period of capital stability for Kintor Pharma through the end of August 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}